Clinical trials: Misoprostol
Reducing Time to Vaginal Delivery, Cervical Ripening
Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery
The purpose of this study is to determine whether the Misoprostol Vaginal Insert (MVI) 200 microgram (mcg) can decrease the time to vaginal delivery compared to the Dinoprostone Vaginal Insert (DVI) 10 milligram (mg) in pregnant…
- Conditions
- Reducing Time to Vaginal Delivery, Cervical Ripening, Induction of Labor
- Trial name
- EXPEDITE (NCT01127581)
- Testing
- MVI 200, Dinoprostone Vaginal Insert (DVI)
- Where
- 34 sites in United States
- Volunteers
- 1,358 people
- Sponsor
- Ferring Pharmaceuticals
Cervical Ripening, Labor, Induced
Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor
The purpose of this study is to determine whether the misoprostol vaginal insert (50 mcg and 100 mcg) can safely and effectively speed time to vaginal delivery compared to Cervidil (R) in women who need to have cervical ripneing…
- Trial name
- NCT00308711
- Testing
- Misoprostol vaginal insert 100 mcg, Misoprostol vaginal insert 50 mcg, Dinoprostone vaginal insert (Cervidil)
- Where
- 52 sites in United States, Canada
- Volunteers
- 1,308 people
- Sponsor
- Ferring Pharmaceuticals
Cervical Ripening, Induction of Labor
Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor
The purpose of this study is to assess the efficacy and safety of the 100, 150 and 200 mcg Misoprostol Vaginal Insert (MVI 100, MVI 150 and MVI 200) for women requiring cervical ripening and induction of labor.
- Trial name
- NCT00828711
- Testing
- MVI 100, MVI 150, MVI 200
- Where
- 11 sites in United States
- Volunteers
- 374 people
- Sponsor
- Ferring Pharmaceuticals
Cervical Ripening, Induction of Labor
Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)
The purpose of this study is to determine the pharmacokinetics (PK) of misoprostol acid for the MVI 200 in women requiring cervical ripening and induction of labor.
- Trial name
- NCT01283022
- Testing
- MVI 200
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ferring Pharmaceuticals
Cervical Priming
Efficacy and Safety Study of the Misoprostol Vaginal Priming Insert (MVPI) Prior to Hysteroscopy
A Phase II, multicenter, double-blind, randomized, placebo-controlled, dose-ranging, study to assess the efficacy and safety of the 100, 200, 400, 800, 1200 and 1600 mcg Misoprostol Vaginal Priming Insert (MVPI) for Women…
- Trial name
- NCT00925938
- Testing
- misoprostol
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Ferring Pharmaceuticals
Gastric Ulcer
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec
This randomized, double-blind, parallel-group, controlled, multi-center clinical trial of 6 months duration is designed to assess the efficacy, tolerability and safety of PN400 versus diclofenac/misoprostol in subjects at high…
- Trial name
- NCT00594854
- Testing
- PN400 (VIMOVO), Diclofenac/Misoprostol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- POZEN